u-PAurokinase type plasminogen activator
u-PAurinary type plasminogen activator
References in periodicals archive ?
In internal lysis, all fibrinolytic components are homogeneously distributed within the clot, whereas in external lysis plasminogen activators, t-PA or u-PA, are acting from the outside of the clot.
The aim of this study is, first, to determine u-PA, t-PA, and PAI-1 levels in the culture media incubated with aortic stenosis valves using different ELISA kits and in a second step to investigate whether there is any correlation between the different actors of the fibrinolytic system and then to correlate their values with the valvular calcium content.
Concentrations of urokinase- and tissue-plasminogen activators (u-PA, t-PA) as well as plasminogen activator inhibitor-1 (PAI-1) were measured in the valve-conditioned media, using ELISA assays according to the manufacturer's instructions (Hyphen Bio Med and Technoclone).
El PAI-1 reacciona con ambos u-PA y t-PA, pero con mayor especificidad para el t-PA.
PAI-2 es un eficiente inhibidor de u-PA, pero es mas lento que PAI-1 (por un factor de 1 a 5 veces, respectivamente) para inhibir al t-PA de doble cadena.
Se utilizo 1 mg para cada uno de los Plgs a una concentracion de 1 mg/ml y a una temperatura constante de 37[grados]C, a los cuales se les adiciono 6.72 [micron]l de u-PA para una concentracion final de 739.2 UI/ml "Solucion activada".
La conversion de los Plgs a Pli, por activacion con u-PA fue monitoreado de acuerdo a la cantidad de sustrato hidrolizado y detectado a [A.sub.405nm] (Figura 3).
Increased levels of u-PA and NO have been implicated in the invasive behaviour of tumour cells.
These cells are major site of synthesis of fibrinolytic proteins, t-PA, u-PA, PAI-1, and the various binding proteins involved in the regulation and surface-localization of EC-mediated fibrinolysis.
Methods: Serum concentrations of VEGF, NO and u-PA were measured in groups of pre-operative breast cancer patients without metastasis (n = 20), post-operative breast cancer patients without metastasis (four wk after the operation, n=20), breast cancer patients with metastasis (n = 23), patients with benign breast disease (n = 11) and healthy female controls (n = 20).